Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-HPV16 L1/Major capsid protein L1 Antibody (H16.14J)

Catalog #:   RVV08808 Specific References (90) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: ELISA, Neutralization, WB
Expression system: Mammalian Cells
Overview

Catalog No.

RVV08808

Expression system

Mammalian Cells

Species reactivity

Human papillomavirus type 16

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

ELISA, Neutralization, WB

Target

L1, Major capsid protein L1

Concentration

2.82 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03101

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

H16.14J

Note

For research use only.

Data Image
  • SDS-PAGE
    SDS PAGE for HPV16 L1/Major capsid protein L1 Antibody (H16.14J)
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16., PMID:29959021

L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine., PMID:29984037

VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris., PMID:30091403

Epitope clustering analysis for vaccine-induced human antibodies in relationship to a panel of murine monoclonal antibodies against HPV16 viral capsid., PMID:30287156

A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses., PMID:30360122

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity., PMID:30560935

Post-treatment human papillomavirus antibody kinetics in cervical cancer patients., PMID:30955486

Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry., PMID:30996086

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity., PMID:31147274

Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein., PMID:31381497

Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines., PMID:31994744

Simultaneous quantification of major capsid protein of human papillomavirus 16 and human papillomavirus 18 in multivalent human papillomavirus vaccines by liquid chromatography-tandem mass spectrometry., PMID:32067760

The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease., PMID:32133000

Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens., PMID:32510304

DRH1 - a novel blood-based HPV tumour marker., PMID:32535546

Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women., PMID:32727491

Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes., PMID:32967963

Phylogeny and In Silico Structure Analysis of Major Capsid Protein (L1) Human Papillomavirus 45 from Indonesian Isolates., PMID:32986347

Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test., PMID:33249381

Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test"., PMID:33254024

Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists., PMID:33309485

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies., PMID:33493568

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP., PMID:33573433

In silico prediction of T-cell and B-cell epitopes of human papillomavirus type 16 L1 protein., PMID:33624357

Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency., PMID:33636291

Inducible expression of human papillomavirus-16 L1 capsomeres in the plastomes of Nicotiana tabacum: Transplastomic plants develop normal flowers and pollen., PMID:33650709

RG1-VLP and Other L2-Based, Broad-Spectrum HPV Vaccine Candidates., PMID:33802456

The Synthesis of Main Capsid Protein of Anogenital Type HPV6 L1 in Plant Expression System on the Basis of Tomato Fruits., PMID:34189649

Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy., PMID:34635698

Germline determinants of humoral immune response to HPV-16 protect against oropharyngeal cancer., PMID:34642315

Genetic variability in minor capsid protein (L2 gene) of human papillomavirus type 16 among Indian women., PMID:35552511

Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway., PMID:35619167

RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer., PMID:35703545

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development., PMID:36263027

Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study., PMID:36322543

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice., PMID:36679860

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas., PMID:36680181

Human papilloma virus-16-specific CD8+ T-cell expansions characterize different clinical forms of lichen planus and not lichen sclerosus et atrophicus., PMID:36922453

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination., PMID:36922512

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice., PMID:37175776

Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope., PMID:37798448

Nano-Sized Chimeric Human Papillomavirus-16 L1 Virus-like Particles Displaying Mycobacterium tuberculosis Antigen Ag85B Enhance Ag85B-Specific Immune Responses in Female C57BL/c Mice., PMID:37896900

A validated polyclonal antiserum-based immunoassay for assessment of HPV 16 L1 relative potency., PMID:38340596

Prevalence of HPV16 L1 protein in oral biopsies: A diagnostic study from Ecuador., PMID:39018933

Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16., PMID:39453911

[A fluorescence immunochromatography method for detection of human papillomavirus type 16 E6 and L1 proteins]., PMID:39584350

Molecular epidemiology of human papillomavirus variants in cervical cancer in India., PMID:39913513

A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies., PMID:40197040

HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopes., PMID:40236113

All-atom MD simulations of the HPV16 capsid., PMID:40475506

Genetic signatures for lineage/sublineage classification of HPV16, 18, 52 and 58 variants. PMID: 33238224

HPV-16 RNA processing. PMID: 18508629

Characterization of major capsid protein (L1) variants of Human papillomavirus type 16 by cervical neoplastic status in Indian women: Phylogenetic and functional analysis. PMID: 31944308

IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation. PMID: 31452045

Comparison of multiplex-serology and ELISA based methods in detecting HPV16 L1 antibody responses in paired saliva and serum samples of healthy men. PMID: 31004663

Genetic Variability in the E6, E7, and L1 Genes of Human Papillomavirus Types 16 and 18 among Women in Saudi Arabia. PMID: 36680149

Humoral Response to HPV16 Proteins in Persons with Anal High-Grade Squamous Intraepithelial Lesion or Anal Cancer. PMID: 32883662

Mapping the B cell epitopes within the major capsid protein L1 of human papillomavirus type 16. PMID: 29959021

The study of immunogenicity of the antigenic protein of high risk oncogenic type of the human papillomavirus HPV16 L1 produced in the plant expression system on the base of transgenic tomato. PMID: 28726109

An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study. PMID: 29475967

Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. PMID: 27107614

A colorimetric aptasensor for the simple and rapid detection of human papillomavirus type 16 L1 proteins. PMID: 33688885

Response to: "Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test". PMID: 33254024

Study results and related evidence do not support use of HPV16 L1 DRH1 antibodies as a cancer screening test. PMID: 33249381

The papillomavirus major capsid protein L1. PMID: 23800545

ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. PMID: 35193933

hnRNP L controls HPV16 RNA polyadenylation and splicing in an Akt kinase-dependent manner. PMID: 28934469

Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients. PMID: 35768785

Astaxanthin Prevents Human Papillomavirus L1 Protein Binding in Human Sperm Membranes. PMID: 30400141

Exploring the roles of HPV16 variants in head and neck squamous cell carcinoma: current challenges and opportunities. PMID: 34749746

Effect of HPV16 L1 virus-like particles on the aggregation of non-functionalized gold nanoparticles. PMID: 28889068

The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context. PMID: 21061438

HPV16 Entry into Epithelial Cells: Running a Gauntlet. PMID: 34960729

E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma. PMID: 29400024

Identification of HPV16's E6 gene in suspected cases of cervical lesions and docking Study of its L1 protein with active components of Echinacea purpurae. PMID: 36032471

Clinicopathological implications of human papilloma virus (HPV) L1 capsid protein immunoreactivity in HPV16-positive cervical cytology. PMID: 24396289

HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. PMID: 23335178

HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer. PMID: 26925750

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay. PMID: 25483632

Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3'-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing. PMID: 25878250

Controlled Hybrid-Assembly of HPV16/18 L1 Bi VLPs in Vitro. PMID: 27998118

HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer. PMID: 31848196

Correlation of HPV16 L1 capsid protein expression in cervical dysplasia with HPV16 DNA concentration, HPV16 E6*I mRNA and histologic outcome. PMID: 19697723

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study. PMID: 35199231

HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions. PMID: 25202103

Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens. PMID: 32510304

Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy. PMID: 34635698

HPV16 L1 diversity and its potential impact on the vaccination-induced immunity. PMID: 32304786

Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway. PMID: 35619167

Mutation Profile of HPV16 L1 and L2 Genes in Different Geographic Areas. PMID: 36680181

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1860

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-HPV16 L1/Major capsid protein L1 Antibody (H16.14J) [RVV08808]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only